Association between activating KIR genes and ALL, including patients with B-ALL and T-ALL
| Gene . | Patients (n = 175), n (%) . | Control subjects (n = 245), n (%) . | Univariate analysis . | Adjusted analysis* . | ||
|---|---|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | |||
| 2DS1 | 39 (22.4) | 102 (41.6) | 0.41 (0.26-0.63) | 5.1 × 10−5 | 0.48 (0.29-0.80) | .005 |
| 2DS2 | 39 (22.3) | 138 (56.3) | 0.22 (0.14-0.34) | 1.5 × 10−11 | 0.27 (0.16-0.44) | 1.14 × 10−7 |
| 2DS3 | 19 (10.9) | 83 (33.9) | 0.24 (0.14-0.41) | 2.8 × 10−7 | 0.44 (0.24-0.80) | .008 |
| 2DS4† | 71 (41.3) | 139 (56.7) | 0.54 (0.36-0.79) | .002 | 0.52 (0.33-0.82) | .005 |
| 2DS5 | 34 (19.5) | 104 (42.4) | 0.33 (0.21-0.52) | 1.5 × 10−6 | 0.43 (0.26-0.72) | .001 |
| 3DS1 | 33 (18.7) | 101 (41.2) | 0.33 (0.21-0.52) | 2.1 × 10−6 | 0.53 (0.32-0.89) | .016 |
| Gene . | Patients (n = 175), n (%) . | Control subjects (n = 245), n (%) . | Univariate analysis . | Adjusted analysis* . | ||
|---|---|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | |||
| 2DS1 | 39 (22.4) | 102 (41.6) | 0.41 (0.26-0.63) | 5.1 × 10−5 | 0.48 (0.29-0.80) | .005 |
| 2DS2 | 39 (22.3) | 138 (56.3) | 0.22 (0.14-0.34) | 1.5 × 10−11 | 0.27 (0.16-0.44) | 1.14 × 10−7 |
| 2DS3 | 19 (10.9) | 83 (33.9) | 0.24 (0.14-0.41) | 2.8 × 10−7 | 0.44 (0.24-0.80) | .008 |
| 2DS4† | 71 (41.3) | 139 (56.7) | 0.54 (0.36-0.79) | .002 | 0.52 (0.33-0.82) | .005 |
| 2DS5 | 34 (19.5) | 104 (42.4) | 0.33 (0.21-0.52) | 1.5 × 10−6 | 0.43 (0.26-0.72) | .001 |
| 3DS1 | 33 (18.7) | 101 (41.2) | 0.33 (0.21-0.52) | 2.1 × 10−6 | 0.53 (0.32-0.89) | .016 |
The prefix KIR is not shown with the gene names.
OR indicates odds ratio; and CI, confidence interval.
Logistic regression analysis adjusted for the effect of other genes in the table.
KIR2DS4 was considered absent when the PCR amplified only the 22-bp deleted amplicon. It was considered present when the nonmutant amplicon was observed on the gel with or without the mutant band.